UK at 'critical moment' as 1-day rise in Covid deaths nears 1,000: Johnson

The UK is at a "critical moment" in the fight against Covid as the single-day rise in the death toll neared 1,000 on Wednesday, the largest increase since April, Prime Minister Boris Johnson said

British PM, Boris Johnson, coronavirus
British Prime Minister Boris Johnson
ANI Europe
2 min read Last Updated : Dec 31 2020 | 7:01 AM IST

The United Kingdom is at a "critical moment" in the fight against COVID-19 as the single-day rise to the country's death toll neared 1,000 on Wednesday, the largest increase since April, Prime Minister Boris Johnson has said.

"Yesterday, sadly, we recorded almost 1,000 deaths across the UK for the first time since April. So at this critical moment, with the prospect of freedom within reach, we've got to redouble our efforts to contain the virus," the prime minister said at a press briefing.

Earlier in the day, the UK Department of Health and Social Care confirmed that 981 people had died due to coronavirus disease-related complications over the preceding 24 hours, the largest single-day increase since the end of April.

The UK also registered 50,023 new positive tests for the coronavirus disease over the past day, health officials said, as the country battles a surge in cases linked to the discovery of a new variant of SARS-CoV-2 that is believed to be more transmissible ...

During the press conference, Johnson said that the government would follow a new immunization strategy, which would delay the administration of a second vaccine dose until 12 weeks after an individual has received their first shot. This scheme, the prime minister said, would give more people the protection offered by a single dose of the vaccine.

The Medicines and Healthcare Products Regulatory Agency on Wednesday morning issued emergency use approval for a vaccine against COVID-19 produced by AstraZeneca and the University of Oxford, the second such vaccine to be cleared for use in the country.

The UK has already begun vaccinating elderly and at-risk individuals with a vaccine produced by Pfizer and BioNTech after the regulatory body issued emergency use approval in early December.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusBoris JohnsonUKCoronavirus VaccineCoronavirus TestsHealth crisis

First Published: Dec 31 2020 | 6:49 AM IST

Next Story